Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Hence, their use in different regions is increasing
Although the study focused on autoimmune patients with diabetes, the findings highlight the potential of GLP-1 receptor agonists in managing cardiovascular risk in the broader autoimmune population
Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
Semaglutide could be the breakthrough you need
US$ 24.90
US$ 27.06
US$ 27.73
US$ 29.75
US$ 19.99
US$ 22.78
US$ 24.43
